Barkhof F, Kappos L, Wolinsky J. Neurology; 2019; e1778-1786.
Authors analyzed 163 individuals from partly blinded phase II trials of ocre and 1656 from double blind phase 3 trials for MS who underwent q 4 week scans, Control group got interferon Beta in phase 3 trials, and 1/3 also got placebo in pahse 2 trials. Relative to placebo, ocrelizumab produced reduction in MRI activity by week 4. Relative to interferon beta 1a, there were less ARR by week eight.
Authors analyzed 163 individuals from partly blinded phase II trials of ocre and 1656 from double blind phase 3 trials for MS who underwent q 4 week scans, Control group got interferon Beta in phase 3 trials, and 1/3 also got placebo in pahse 2 trials. Relative to placebo, ocrelizumab produced reduction in MRI activity by week 4. Relative to interferon beta 1a, there were less ARR by week eight.
No comments:
Post a Comment